

Online Supplementary Table S1. Mean (SD) clinical efficacy and patient-reported outcomes

		Double-blind phase		Open-label phase				
		Wk 12	Wk 16	Wk 24	Wk 32	Wk 40	Wk 48	
N=Pts in study	ETN/ETN	N=101	N=99	N=98	N=94	N=93	N=91	
	PBO/ETN	N=106	N=104	N=103	N=100	N=99	N=99	
ASDAS-CRP	ETN/ETN	1.7 (0.9)	1.6 (0.9)	1.5 (0.9)	1.6 (0.9)	1.4 (0.9)	1.4 (1.0)	
	PBO/ETN	2.3 (1.1)	1.6 (0.9)	1.4 (0.9)	1.4 (0.9)	1.4 (0.9)	1.3 (0.9)	
BASDAI	ETN/ETN	3.6 (2.4)	3.3 (2.2)	3.1 (2.3)	3.2 (2.3)	2.7 (2.2)	2.8 (2.2)	
	PBO/ETN	4.3 (2.2)	3.0 (2.2)	2.7 (2.1)	2.7 (2.1)	2.6 (2.1)	2.5 (2.1)	
BASFI	ETN/ETN	2.6 (2.3)	2.5 (2.3)	2.4 (2.3)	2.4 (2.4)	2.1 (2.1)	2.1 (2.0)	
	PBO/ETN	3.0 (2.4)	2.1 (2.0)	2.0 (1.9)	1.8 (1.9)	1.7 (1.8)	1.7 (1.8)	
BASMI	ETN/ETN	1.0 (1.3)	0.9 (1.3)	0.9 (1.1)	0.8 (1.0)	0.9 (1.0)	0.8 (1.1)	
	PBO/ETN	1.0 (1.2)	0.8 (1.1)	0.8 (1.2)	0.7 (1.1)	0.7 (1.0)	0.7 (1.1)	
Total back pain	ETN/ETN	3.2 (2.6)	2.8 (2.5)	2.8 (2.5)	2.9 (2.5)	2.2 (2.3)	2.4 (2.5)	
	PBO/ETN	4.1 (2.6)	2.8 (2.5)	2.5 (2.5)	2.6 (2.5)	2.2 (2.4)	2.3 (2.2)	
SF-36 PCS	ETN/ETN	43.7 (8.9)	na	44.4 (9.2)	na	na	45.8 (9.3)	
	PBO/ETN	41.0 (7.8)	na	44.6 (8.9)	na	na	45.9 (7.9)	
SF-36 MCS	ETN/ETN	45.8 (10.7)	na	46.0 (12.2)	na	na	46.7 (10.7)	
	PBO/ETN	45.7 (11.2)	na	48.3 (9.1)	na	na	47.3 (11.1)	
EQ-5D Utility Score	ETN/ETN	0.70 (0.26)	0.71 (0.27)	0.74 (0.23)	na	0.77 (0.26)	0.76 (0.23)	
	PBO/ETN	0.67 (0.27)	0.75 (0.24)	0.78 (0.19)	na	0.76 (0.23)	0.80 (0.15)	
N=Pts with Work Data	ETN/ETN	N=48	N=49	N=45	N=46	N=45	N=45	
	PBO/ETN	N=50	N=46	N=43	N=43	N=47	N=45	
WPAI Overall	ETN/ETN	26.7 (25.1)	27.1 (23.2)	26.3 (28.0)	26.3 (23.9)	18.4 (18.8)	20.6 (19.6)	
	PBO/ETN	34.4 (27.1)	23.4 (21.8)	26.1 (25.3)	27.0 (24.0)	21.4 (19.5)	23.6 (23.3)	

Analyses performed on mITT, LOCF population for ASDAS-CRP, BASDAI, BASFI, BASMI, total back pain; mITT, observed case population for SF-36 PCS, SF-36 MCS, EQ-5D utility score, WPAI Overall.

ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score based C-reactive protein; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; EQ-5D, EuroQoL 5 Dimensions; ETN, etanercept; LOCF, last observation carried forward; MCS, mental component summary; mITT, modified intention-to-treat; na, not available, ns, non-significant; PCS, physical component summary; PBO, placebo; pts, patients; SEM, standard error of the mean; SF-36, 36-item Short Form Health Survey; wk, week; WPAI, Work Productivity and Activity Impairment Questionnaire.